-
MoHFW may approve Covid vaccine this month for those aged between 12 years and 18 years
-
Hyderabad: Bharat Biotech completed the Phase 2/3 trials of Covid-19 vaccine, Covaxin for use in children under 18 years of age and is expected to submit the data by next week to the DCGI, Chairman and Managing Director of Bharat Biotech International Ltd, Krishna Ella said on Tuesday here. Speaking to reporters, he said Covaxin […]
-
Union minister of Health and Family Welfare Mansukh Mandaviya formally launched the Covaxin batches. Dr Krishna Ella, CMD, Bharat Biotech and Suchitra Ella, joint managing director, Bharat Biotech were also present at the launch.
-
IVI is advancing clinical development of BBV87 through a phase II/III randomised, controlled trial to evaluate the safety and immunogenicity of a 2-dose regimen of BBV87 chikungunya vaccine
-
Nod for Zydus Cadila'd Covid vaccine for children will help India ramp up its vaccination programme quickly
-
Output of Covaxin drug substance will be adequate for 3 to 4 million doses a month and from December it will increase to 10 million doses a month
-
The approval has been received from the National Institute of Pharmacy and Nutrition, Hungary, certifying the GMP for the manufacture of Covaxin.
-
More than half of the adult population has yet to receive even a single dose, despite a slight improvement in coverage in July
-
The vaccine is used for the prevention of rotavirus infection, which is prevalent in infants and young children
-
The company had supplied about four billion doses to about 125 countries and will continue to ramp up production at its four plants in the country, said Suchitra Ella, co-founder of Bharat Biotech
-
Efficacy data also demonstrates 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta variant, the company said in a statement while announcing its phase 3 data analysis.
-
Covaxin comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus.
-
Dr Krishna Ella, CMD, Bharat Biotech, an alumnus of Anand Niketan College of Agriculture of Warora (Maharashtra), learnt in one of his regular call with the Anandwan management that the inmates were affected by the pandemic
-
It is reprehensible to invoke religious fears to spread falsehood against vaccines
-
Shortly afer the reports went viral after two major news channels began flashing the news, Bharat Biotech refuted these reports
-
"New born calf serum is used in the manufacturing of viral vaccines. It is used for the growth of cells, but neither used in growth of SARS CoV2 virus nor in the final formulation," the company said in a statement.
-
Compared to the first wave, the number of positive cases and their severity has increased among children this time.
-
Hyderabad firm stated that the data from efficacy and safety follow-up of Covaxin’s phase III trial is being analysed and compiled, and it will soon make the data from the final analysis public
-
With herd immunity and a significant percentage of the US population vaccinated, the pandemic is reducing, and keeping this in view, the USFDA communicated that no new emergency use authorization would be approved for new Covid-19 vaccines
-
The FDA recommended Ocugen to "pursue a Biologics Licence Application (BLA) submission instead of an EUA application" and "requested additional information and data".